Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moiety
摘要:
The in vitro potency of orally-active mercaptoacyl matrix metalloproteinase inhibitors is increased by the introduction of appropriate substituents on the mercaptoacyl moiety. (C) 1997 Elsevier Science Ltd.
Selective MMP inhibitors having reduced side-effects
申请人:——
公开号:US20020035065A1
公开(公告)日:2002-03-21
The subject invention pertains to matrix metalloproteinase (MMP) inhibitors that exhibit an IC
50
of below 10
−4
M against MMP and have substantially no activity against non-MMP metalloproteinase-related events. The MMP inhibitors of the invention have reduced side-effects, especially with respect to joint pain.
[EN] SELECTIVE MMP INHIBITORS HAVING REDUCED SIDE-EFFECTS<br/>[FR] INHIBITEURS SELECTIFS DE LA METALLOPROTEASE MATRICIELLE PRESENTANT DES EFFETS SECONDAIRES REDUITS
申请人:DARWIN DISCOVERY LIMITED
公开号:WO1998039024A1
公开(公告)日:1998-09-11
(EN) A matrix metalloproteinase (MMP) inhibitor that exhibits an IC50 of below 10-4M against MMP and has substantially no activity against non-MMP metalloproteinase-related events has reduced side-effects, especially with respect to joint pain.(FR) L'invention concerne un inhibiteur de la métalloprotéase matricielle qui présente une concentration inhibitrice 50 de moins de 10-4M contre la métalloprotéase matricielle, et n'exerce sensiblement aucune activité contre les évènements non liés à la métalloprotéase matricielle. Cet inhibiteur présente des effets secondaires réduits, en particulier, dans le domaine des douleurs articulaires.
SELECTIVE MMP INHIBITORS HAVING REDUCED SIDE-EFFECTS
申请人:Darwin Discovery Limited
公开号:EP0981366B1
公开(公告)日:2004-01-21
Method for Preparing 4-[9-(6-Aminopurine)]-2-(S)-Hydroxyl-Butyric Acid Methyl Ester
申请人:Nan Fajun
公开号:US20110201810A1
公开(公告)日:2011-08-18
The present invention discloses a novel method for preparing and purifying 4-(6-Amino-purin-9-yl)-2(S)-hydroxy-butyric acid methyl ester. The preparation started from cheap and easily available L-malic acid, which was transformed to intermediate I after simultaneous protection of the groups of 1-carboxyl and 2-hydroxyl. The intermediate I was selectively reduced to intermediate alcohol II, whose hydroxyl group was further transformed to an easily leaving group to afford intermediate III. The intermediate III was nucleophilically substituted with adenine to afford intermediate IV. The intermediate IV was deprotected and methyl-esterified simultaneously in methanol in the presence of an acid or a base to afford crude 4-(6-Amino-purin-9-yl)-2(S)-hydroxy-butyric acid methyl ester, which was purified by recrystallization to afford the purified product. Comparing with the prior preparation methods, the present method has advantages in low cost, mild conditions, high retention of the chiral center during the reaction, high productivity, great improvement in the quality and yield of the product and great decrease in cost, and thus is suitable for the production on a large scale.